Irbesartan 138402-11-6
Irbesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.
Clinical use
Indications
As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes, hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).
Combination with diuretic
Irbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including Irda, CoIrda, CoAprovel, Karvezide, Avalide and Avapro HCT.
No benefits seen in trial for certain kind of heart failure
A large randomized trial following 4100+ men and women with heart failure and normal ejection fraction (>=45%) over 4+ years found no improvement in study outcomes or survival with irbesartan as compared to placebo.
Market
BMS annual sales approx $1. 3bn. Sanofi-aventis annual sales approx $2. 1bn. Patent expires in march 2012 currently.
| Systematic (IUPAC) name: | 2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one |
|---|---|
| Irbesartan CAS number: | 138402-11-6 |
| ATC code: | C09CA04 |
| PubChem: | 3749 |
| DrugBank: | APRD00413 |
| Formula: | C25H28N6O1 |
| Molecular mass: | 428.53 g/mol |
| Irbesartan Assay/Purity: | Typically NLT 98% |
